Pharmaceutical

FDA approves Mesoblast’s Ryoncil for SR-aGvHD treatment

Mesoblast has gained US FDA approval for its mesenchymal stromal cell (MSC) therapy, Ryoncil (remestemcel-L), to treat SR-aGvHD.

Dec 21, 2024 - 06:00
FDA approves Mesoblast’s Ryoncil for SR-aGvHD treatment
Mesoblast has gained US FDA approval for its mesenchymal stromal cell (MSC) therapy, Ryoncil (remestemcel-L), to treat SR-aGvHD.
Read the original article

Tags:

Previous Article

Vertex’s stock hurt after non-opioid pain drug shows benefit similar to placebo

Next Article

MSD makes obesity play in up to $2bn deal for Hansoh’s GLP-1RA asset

What's Your Reaction?

like

dislike

love

funny

angry

sad

wow

Related Posts

Ipilimumab by Bristol-Myers Squibb for Metastatic Transitional (Urothelial) Tract Cancer: Likelihood of Approval

Ipilimumab by Bristol-Myers Squibb for Metastatic Trans...

Aug 30, 2023

STAT+: San Diego biotech Neurocrine Biosciences joins PhRMA

STAT+: San Diego biotech Neurocrine Biosciences joins P...

Feb 23, 2024

J&J and Legend’s Carvykti scores early line approval for MM by FDA

J&J and Legend’s Carvykti scores early line approval fo...

Apr 9, 2024